BioSpace News Archive

Neos Therapeutics, Inc. announced that it has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA, Inc. to resolve all ongoing litigation involving Neos’ patents protecting its Cotempla XR-ODT® extended-release orally disintegrating tablets and Teva’s Abbreviated New Drug Application filed with the U.S. Food and Drug Administration to market a generic version of that product.

Professor Jackie Y. Ying who heads A*STAR’s NanoBio Lab in Singapore has won the 2018 Turkish Academy of Sciences Academy Prize in Science and Engineering Sciences

Move in line with ‘National Program for the Combat of Obesity in Children and Adolescents 2021'

In an endeavour to support development of Fertility and Reproductive Medicine in Oman, IVI Middle East Fertility Clinic Muscat– has organised a series of programmes for the medical community, in association with the Oman Society of Obstetrics and Gynecology

Bio-Path Holdings, Inc. provides an update from several clinical development programs and a 2019 business overview

PwC recently came out with the latest version of their annual R&D spending report, and while there is a lot of interesting information to digest in this report, there are a few companies in particular that stand out within the field of biotechnology.

First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa

Retrophin, Inc. announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that often leads to end-stage renal disease

As technology advances, more of it becomes automated. While some manufacturing industries have long utilized automation throughout their processes and product production, the biopharma industry is comparatively behind the times.

Follow-up investigations by the Wall Street Journal suggest that He Jiankui’s story may be just the tip of the iceberg of sloppy and unmonitored clinical trials using CRISPR in China.